Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Indications and Limitations of Use Victoza (liraglutide) injection 1.2 mg or 1.8 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease
Powered by a dual incretin mechanism, this innovative formulation is rapidly becoming one of the most in-demand anti-diabetic and obesity management injections worldwide
Although weight loss outcomes differed from person to person, the overall results showed meaningful reductions in body weight: Patients treated for obesity lost an average of 8.4% of their body weight before stopping treatment and regained an average of 0.5% one year later
Wind down routine
